MINNEAPOLIS and SAN RAFAEL, Calif. , April 18, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a services agreement between its wholly owned subsidiary, Helomics and the National Alopecia Areata Foundation (NAAF), which serves the

Collaboration Receives $300,000 CAD Grant to Further Develop and Commercialize TumorGenesis Oncology Discovery Technologies MINNEAPOLIS , April 16, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly owned subsidiary,

Helomics to provide CRO services and its D-CHIP artificial intelligence (AI) platform to SpeciCare for their PIONEER Initiative functional precision medicine trial PITTSBURGH , April 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today

MINNEAPOLIS , April 09, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a collaboration between its wholly owned subsidiary, Helomics, and Viome, a new kind of healthcare company transforming health at the molecular level, to study

MINNEAPOLIS , April 05, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision Therapeutics” or “the Company”), today announced the completion of its merger with Helomics Holding Corporation (“Helomics”), which has become the Company’s wholly owned subsidiary, providing

MINNEAPOLIS , April 01, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to Women’s Oncology, announced today financial results for the quarter and fiscal year ended December 31, 2018 and

MINNEAPOLIS , March 27, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced the pricing of its previously announced public offering of its common stock and warrants to purchase common stock, with anticipated gross proceeds of up to

MINNEAPOLIS , March 26, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a proposed public offering of its common stock and warrants to purchase common stock. The offering is subject to market and other conditions, and there can be

MINNEAPOLIS , March 25, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (the “Company”) announced today that at a special meeting of stockholders held on March 22, 2019 , the Company’s stockholders approved the Amended and Restated Agreement and Plan of Merger, dated as of

Conference Call to be held April 1, 2019, at 4:30pm Eastern Time MINNEAPOLIS , March 25, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces that it will report Fiscal Year 2018 financial results for the period ended December 31, 2018 ,